169 related articles for article (PubMed ID: 38558246)
1. Long noncoding RNA TUG1 promotes cisplatin resistance in ovarian cancer via upregulation of DNA polymerase eta.
Sonobe R; Yang P; Suzuki MM; Shinjo K; Iijima K; Nishiyama N; Miyata K; Kataoka K; Kajiyama H; Kondo Y
Cancer Sci; 2024 Jun; 115(6):1910-1923. PubMed ID: 38558246
[TBL] [Abstract][Full Text] [Related]
2. Long Non-coding RNA CCAT1 Sponges miR-454 to Promote Chemoresistance of Ovarian Cancer Cells to Cisplatin by Regulation of Surviving.
Wang DY; Li N; Cui YL
Cancer Res Treat; 2020 Jul; 52(3):798-814. PubMed ID: 32124583
[TBL] [Abstract][Full Text] [Related]
3. The cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation.
Wang H; Fang L; Jiang J; Kuang Y; Wang B; Shang X; Han P; Li Y; Liu M; Zhang Z; Li P
Cell Death Dis; 2018 Oct; 9(11):1103. PubMed ID: 30375398
[TBL] [Abstract][Full Text] [Related]
4. A PolH Transcript with a Short 3'UTR Enhances PolH Expression and Mediates Cisplatin Resistance.
Zhang J; Sun W; Ren C; Kong X; Yan W; Chen X
Cancer Res; 2019 Jul; 79(14):3714-3724. PubMed ID: 31064846
[TBL] [Abstract][Full Text] [Related]
5. HDAC1 Silencing in Ovarian Cancer Enhances the Chemotherapy Response.
Liu X; Yu Y; Zhang J; Lu C; Wang L; Liu P; Song H
Cell Physiol Biochem; 2018; 48(4):1505-1518. PubMed ID: 30071534
[TBL] [Abstract][Full Text] [Related]
6. MiR-338-3p Enhances Ovarian Cancer Cell Sensitivity to Cisplatin by Downregulating WNT2B.
Niu Q; Liu Z; Gao J; Wang Q
Yonsei Med J; 2019 Dec; 60(12):1146-1156. PubMed ID: 31769245
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of AXL enhances chemosensitivity of human ovarian cancer cells to cisplatin via decreasing glycolysis.
Tian M; Chen XS; Li LY; Wu HZ; Zeng D; Wang XL; Zhang Y; Xiao SS; Cheng Y
Acta Pharmacol Sin; 2021 Jul; 42(7):1180-1189. PubMed ID: 33149145
[TBL] [Abstract][Full Text] [Related]
8. Cancer-Specific Targeting of Taurine-Upregulated Gene 1 Enhances the Effects of Chemotherapy in Pancreatic Cancer.
Tasaki Y; Suzuki M; Katsushima K; Shinjo K; Iijima K; Murofushi Y; Naiki-Ito A; Hayashi K; Qiu C; Takahashi A; Tanaka Y; Kawaguchi T; Sugawara M; Kataoka T; Naito M; Miyata K; Kataoka K; Noda T; Gao W; Kataoka H; Takahashi S; Kimura K; Kondo Y
Cancer Res; 2021 Apr; 81(7):1654-1666. PubMed ID: 33648930
[TBL] [Abstract][Full Text] [Related]
9. Novel role of lncRNA CHRF in cisplatin resistance of ovarian cancer is mediated by miR-10b induced EMT and STAT3 signaling.
Tan WX; Sun G; Shangguan MY; Gui Z; Bao Y; Li YF; Jia ZH
Sci Rep; 2020 Sep; 10(1):14768. PubMed ID: 32901049
[TBL] [Abstract][Full Text] [Related]
10. Long noncoding RNA TUG1 facilitates cell ovarian cancer progression through targeting MiR-29b-3p/MDM2 axis.
Yang X; Xin N; Qu HJ; Wei L; Han Z
Anat Rec (Hoboken); 2020 Dec; 303(12):3024-3034. PubMed ID: 31930662
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-302 represses epithelial-mesenchymal transition and cisplatin resistance by regulating ATAD2 in ovarian carcinoma.
Ge T; Liu T; Guo L; Chen Z; Lou G
Exp Cell Res; 2020 Nov; 396(1):112241. PubMed ID: 32835657
[TBL] [Abstract][Full Text] [Related]
12. Long non-coding RNA TUG1 enhances chemosensitivity in non-small cell lung cancer by impairing microRNA-221-dependent PTEN inhibition.
Guo S; Zhang L; Zhang Y; Wu Z; He D; Li X; Wang Z
Aging (Albany NY); 2019 Sep; 11(18):7553-7569. PubMed ID: 31532756
[TBL] [Abstract][Full Text] [Related]
13. The miRNA mir-582-3p suppresses ovarian cancer progression by targeting AKT/MTOR signaling
Dai T; Liang J; Liu W; Zou Y; Niu F; Li M; Zhang H; Li C; Fan M; Cui G
Bioengineered; 2021 Dec; 12(2):10771-10781. PubMed ID: 34793263
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of Foxo3 and TRIM31 by miR-551b in side population promotes cell proliferation, invasion, and drug resistance of ovarian cancer.
Wei Z; Liu Y; Wang Y; Zhang Y; Luo Q; Man X; Wei F; Yu X
Med Oncol; 2016 Nov; 33(11):126. PubMed ID: 27743201
[TBL] [Abstract][Full Text] [Related]
15. Recovery of miR-139-5p in Ovarian Cancer Reverses Cisplatin Resistance by Targeting C-Jun.
Jiang Y; Jiang J; Jia H; Qiao Z; Zhang J
Cell Physiol Biochem; 2018; 51(1):129-141. PubMed ID: 30439707
[TBL] [Abstract][Full Text] [Related]
16. Enhanced expression of DNA polymerase eta contributes to cisplatin resistance of ovarian cancer stem cells.
Srivastava AK; Han C; Zhao R; Cui T; Dai Y; Mao C; Zhao W; Zhang X; Yu J; Wang QE
Proc Natl Acad Sci U S A; 2015 Apr; 112(14):4411-6. PubMed ID: 25831546
[TBL] [Abstract][Full Text] [Related]
17. Anticancer potential of TUG1 knockdown in cisplatin-resistant osteosarcoma through inhibition of MET/Akt signalling.
Zhou Q; Hu T; Xu Y
J Drug Target; 2020 Feb; 28(2):204-211. PubMed ID: 31305159
[TBL] [Abstract][Full Text] [Related]
18. LncRNA HOXA11-AS Promotes Proliferation and Cisplatin Resistance of Oral Squamous Cell Carcinoma by Suppression of miR-214-3p Expression.
Wang X; Li H; Shi J
Biomed Res Int; 2019; 2019():8645153. PubMed ID: 31275988
[TBL] [Abstract][Full Text] [Related]
19. Deregulation of miR-128 in ovarian cancer promotes cisplatin resistance.
Li B; Chen H; Wu N; Zhang WJ; Shang LX
Int J Gynecol Cancer; 2014 Oct; 24(8):1381-8. PubMed ID: 25248111
[TBL] [Abstract][Full Text] [Related]
20. Hypoxia induces chemoresistance of esophageal cancer cells to cisplatin through regulating the lncRNA-EMS/miR-758-3p/WTAP axis.
Zhu ZJ; Pang Y; Jin G; Zhang HY; Wang WH; Liu JW; Tuo GX; Wu P; Yang Y; Wang ZQ; Wang K
Aging (Albany NY); 2021 Jun; 13(13):17155-17176. PubMed ID: 34081626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
